GLP-1R Agonists – Label Extensions/Drug Repurposing: Market Overview

GLP-1R Agonists – Label Extensions/Drug Repurposing: Market Overview

Summary

This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity.

The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties.

GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets.

Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.

Scope

• Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation.
• Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing.
• Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas.
• Overview of current major players in the GLP-1RAs space and potential future players.
• GLP-1RAs global market outlook and deals overview.

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future.
• Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.